Treating the many faces of respiratory disease

The National Asthma Council currently estimates that two million Australians suffer from asthma, one of the most common respiratory diseases.

The most recent figures indicate that 1 in every 4 children, 1 in every 7 adolescents and 1 in every 10 adults suffer from asthma. At the same time, other respiratory diseases like allergic rhinitis (hay fever), common during the spring months, affect up to 20% of Australians and significantly interfere with their ability to concentrate and fully participate in work and play.

AstraZeneca Australia is committed to improving the health and quality of life for individuals suffering from respiratory disease. By providing a full range of innovative products and inhalation devices, AstraZeneca is helping physicians treat asthma and rhinitis in both adults and children. In particular, the Turbuhaler, an inspiratory flow-driven, multidose dry-powder inhaler is a key feature in our asthma products portfolio.

Key Products

The key products in the AstraZeneca respiratory range include:

• Symbicort® (budesonide/eformoterol)
• Pulmicort (budesonide)
• Oxis (eformoterol)
• Bricanyl (terbutaline)
• Rhinocort (budesonide)

Our research programme also continues to focus on the development of new drugs for the treatment of respiratory diseases and innovative systems for direct drug delivery to the airways.